MedTrace Logo

Essential Amino Acids and Parkinsons Disease

NCT06604065 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-03-12

No results posted yet for this study

Summary

Parkinson's disease is a neuromuscular disease that is relatively common in elderly that has many potentials symptoms, including a variety of physical features that together reduce quality of life. The Study Team have developed a nutritional supplement (AMS2434) based on essential amino acids that targets improving muscle health and brain neurotransmitter balance. This protocol will determine in individuals with PD the effect of AMS2434 on muscle protein synthesis, neurotransmitter production, and mood and cognition.

Conditions

  • Parkinson Disease

Interventions

DRUG

AMS2434 (amino acids)

The proprietary composition includes leucine, valine, isoleucine, lysine, phenylalanine, threonine, tyrosine, histidine, and methionine. Small amounts of non-caloric flavorings are also included.

DRUG

Placebo

Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Robert R Wolfe, Ph.D. · University of Arkansas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2026-03-09
Completion
2026-03-09
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06604065 on ClinicalTrials.gov